Catalog No.
KDK13901
Description
PRINCIPLE OF THE ASSAY
This assay employs the quantitative competitive enzyme immunoassay technique. An antibody specific for Semaglutide has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled Semaglutide and then pipetted into the wells. Semaglutide in the sample competitively binds to the pre-coated antibody with biotin-labeled Semaglutide. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Semaglutide bound in the initial step. The color development is stopped and the intensity of the color is measured.
Applications
Used for the quantitative determination of Semaglutide concentration in serum and plasma.
Detection method
Colorimetric
Sample type
Plasma, Serum
Assay type
Quantitative
Range
15.63 - 1000 ng/mL
Sensitivity
13.48 ng/mL
Precision
Intra-Assay Precision (Precision within an assay): <20%
Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): <20%
Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.
|
|
Intra-Assay Precision
|
Inter-Assay Precision
|
|
Sample
|
1
|
2
|
3
|
1
|
2
|
3
|
|
n
|
16
|
16
|
16
|
24
|
24
|
24
|
|
Mean (ng/mL)
|
435.6
|
93.7
|
22.0
|
482.1
|
115.2
|
30.8
|
|
Standard deviation
|
31.7
|
4.6
|
1.5
|
49.7
|
9.2
|
3.9
|
|
CV (%)
|
7.3
|
4.9
|
6.9
|
10.3
|
8.0
|
12.6
|
Recovery
80-120%
Shipping
2-8 ℃
Stability and Storage
When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.
Alternative Names
CAS: 910463-68-2, Semaglutide, Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217
Progress and challenges in obesity pharmacotherapy: semaglutide as a milestone., PMID:40515833
[Weight reduction with incretin mimetics-Opportunities and risks]., PMID:40514554
A biodegradable suction patch for sustainable transbuccal peptide delivery., PMID:40513668
Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis., PMID:40513177
2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure: A Report of the American College of Cardiology., PMID:40512113
Addressing obesity and subsequent cardiovascular risk in primary care: the relevance of high- and low-resource settings., PMID:40512090
Key takeaways from the updated multidisciplinary European MASLD guidelines., PMID:40510733
Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes., PMID:40510603
Oral semaglutide for the treatment of obesity: a retrospective real-world study., PMID:40510489
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies., PMID:40507553
Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): a phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia., PMID:40506208
Semaglutide for clozapine-treated patients with schizophrenia., PMID:40506202
Comparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data., PMID:40503067
Efficacy of the GLP-1 receptor agonist, semaglutide, in abstinence from illicit and nonprescribed opioids in an outpatient population with treatment-refractory OUD: A randomized, double-blind, placebo-controlled clinical trial protocol., PMID:40502777
Real-world comparative outcomes of GLP-1 RA and semaglutide prescription among individuals with type 2 diabetes., PMID:40502555
Effect of Semaglutide on C-peptide levels in patients with type 2 diabetes., PMID:40501244
Semaglutide-A ray of hope for CKD in diabetic patients., PMID:40500852
Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 (GLP-1) conjugates modified with dual fatty acids and a proline-alanine-serine (PAS) polypeptide., PMID:40499315
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment., PMID:40497223
Clinical Profile and Prognosis of Patients With Acute Decompensated Heart Failure Who Met the Obesity-Related Eligibility for Subcutaneous Semaglutide - Findings From the CURE-HF Registry., PMID:40497126
Mitochondrial dysfunction characterises the multigenerational effects of maternal obesity on MASLD., PMID:40496439
Finerenone and semaglutide: Role in heart failure with reduced ejection fraction., PMID:40496391
Neuroprotective and cognitive benefits of Semaglutide: Insights into the underlying molecular mechanisms., PMID:40494410
Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations., PMID:40493329
Impact of semaglutide on health outcomes and mood in obese heart failure patients: a retrospective analysis., PMID:40493069
Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status., PMID:40491239
Harnessing Surface Hydrophilicity of Inhalable Nanoparticles for Precision Delivery of Glucagon-like Peptide-1 Receptor Agonists or Anti-Asthmatic Therapeutics., PMID:40490304
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database., PMID:40490170
Effect of pH, buffers, molarity, and temperature on solution state degradation of semaglutide using LC-HRMS: A preformulation protocol for peptide drug delivery., PMID:40490042
Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: A Systematic Review and Meta-Analysis., PMID:40489581
External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes., PMID:40489337
Worth the Weight? The Challenges of Administering the Glucagon-Like Peptide 1 Receptor Agonist Semaglutide With Long-Term Olanzapine Use in a Patient With Schizophrenia., PMID:40488719
Association of GLP-1 Receptor Agonists with Liver-Related Outcomes and All-Cause Mortality in Patients with Harmful Alcohol Use: A Target Trial Emulation Study., PMID:40488647
Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea., PMID:40487675
Pregnancy outcomes following first trimester exposure to semaglutide., PMID:40487375
Improved total shoulder arthroplasty outcomes associated with semaglutide utilization in patients with type II diabetes: a promising new addition to preoperative optimization., PMID:40486798
Effects of Tirzepatide on Patients With Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Retrospective Cohort Study., PMID:40486301
GLP-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate PAD., PMID:40484062
Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial., PMID:40482671
Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial., PMID:40482670
The Obesity Paradox of Cardiovascular Outcomes in Patients with Diabetes Mellitus., PMID:40481922
Tirzepatide Outperforms Semaglutide in Head-to-Head Obesity Trial., PMID:40478570
Research letter: the global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD) current status and future prospects., PMID:40474833
Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels., PMID:40473254
CROI 2025: neuropsychiatric complications in people with HIV., PMID:40472384
Prescriptions for Obesity Medications Among Adolescents Aged 12-17 Years with Obesity - United States, 2018-2023., PMID:40471858
Semaglutide Modulates Proinflammatory Epicardial Adipogenesis With Paracrine Effects on hiPSC-Atrial Cardiomyocytes., PMID:40471762
Beyond GLP-1: efficacy and safety of dual and triple incretin agonists in personalized type 2 diabetes care-a systematic review and network meta-analysis., PMID:40471293
Letter: Amiodarone-Induced Thyrotoxicosis Following Semaglutide-Associated Weight Loss., PMID:40470537
Glucagon-like peptide-1 receptor agonist use prior to spinal surgery results in reduced postoperative length of stay: A propensity-score matched analysis., PMID:40470002
For research use only. Not for human or drug use.
